Table 2.

Cell-cycle analysis of SKOV-3 and OVCAR8 cells

SKOV-3OVCAR-8
% G1 (SD)% S (SD)% G2–M (SD)% G1 (SD)% S (SD)% G2–M (SD)
24 h
Control (PBS)58.0 (0.9)21.1 (0.6)20.9 (0.8)Control (PBS)39.8 (0.9)40.9 (0.5)19.3 (0.3)
LB100 (5 μmol/L)51.4 (1.5)19.7 (0.8)28.9 (1.2)LB100 (2 μmol/L)45.4 (1.5)37.0 (1.6)17.6 (0.4)
Cisplatin (18 μmol/L)49.8 (2.3)33.6 (1.8)16.6 (1.3)Cisplatin (5 μmol/L)4.6 (2.0)81.9 (1.6)13.4 (0.6)
Cisplatin (18 μmol/L) + LB100 (5 μmol/L)55.1 (1.2)26.6 (2.2)18.3 (2.9)Cisplatin (5 μmol/L) + LB100 (2 μmol/L)18.5 (0.4)59.2 (1.0)22.3 (0.7)
48 h
Control (PBS)58.0 (0.9)14.8 (0.5)19.4 (0.9)Control (PBS)60.8 (0.9)28.0 (0.2)11.3 (0.3)
LB100 (5 μmol/L)47.2 (1.9)30.2 (3.1)25.1 (0.8)LB100 (2 μmol/L)55.3 (0.4)29.9 (1.1)14.9 (1.5)
Cisplatin (18 μmol/L)40.4 (0.8)38.4 (0.5)21.2 (1.0)Cisplatin (5 μmol/L)0.85 (0.3)20.7 (2.1)78.5 (2.2)
Cisplatin (18 μmol/L) + LB100 (5 μmol/L)50.4 (4.1)24.7 (1.6)25.0 (3.1)Cisplatin (5 μmol/L) + LB100 (2 μmol/L)0.98 (0.2)32.6 (0.7)66.5 (0.5)